Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

1 envelope glycoprotein. In GeoVax's second generation vaccine, the DNA prime co-expresses GM-CSF with the virus-like particles, delivering a normal human protein that stimulates immune responses to the site of vaccination. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as the vaccines' safety.

About HIV/AIDSAIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally and it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus. Every 9-1/2 minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B, and C. GeoVax vaccines are currently designed to function against clade B.

For more information, please visit www.geovax.com.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 DURECT Corporation (Nasdaq: ... a multi-dose Phase 1 clinical trial of an ... DURECT,s Epigenomic Regulator Program.  DUR-928 is an endogenous, ... broad applicability in metabolic diseases such as nonalcoholic ...  It may also play an important role in ...
(Date:3/30/2015)... , March 30, 2015   GlassesUSA , the ... closing of $12.5 million in new financing led by ... The funding will further GlassesUSA,s aggressive business growth and accelerate ... market of online eyewear, both B2C and B2B. ... , COO Eldad Rothman , and CTO Roy ...
(Date:3/30/2015)... 2015  Zimmer Holdings, Inc. (NYSE and SIX: ... ("EC") has conditionally cleared Zimmer,s proposed acquisition of ... upon Zimmer entering into agreements with a suitable ... package previously submitted to the EC.  Zimmer expects ... term.  As previously announced, the proposed transaction also ...
Breaking Medicine Technology:DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 2Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 3Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 4Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 5
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... has been filed in California Superior Court on ... a serious heart birth defect after his mother was ... pregnancy. According to the March 6th filing in Alameda ... to alleviate nausea and vomiting that she experienced in ...
(Date:3/30/2015)... 2015 On March 11, 2015, Elle Magazine, ... Fat,” details six new treatment options for dealing with stubborn, ... is a topical product. The other three technologies use devices ... ) or freezing cold ( CoolSculpting ) to kill fat ... available to us to permanently remove unwanted fat," says Dr. ...
(Date:3/30/2015)... USA (PRWEB) March 30, 2015 In ... on March 17th, Governor Chris Christie is championing effective ... use disorders.New Jersey is scrambling to recover funds to ... the best care for victims of drug and alcohol ... services to those plagued by substance use disorders in ...
(Date:3/30/2015)... This report studies the global pharmacovigilance and drug ... 2014 to 2019. This market is expected to ... to 2019. , Further Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=16831714 ... and drug safety software market has been classified ... namely, adverse event reporting software, drug safety audits ...
(Date:3/30/2015)... March 30, 2015 Dr. Daniel Shapiro, one ... AZ, was recently featured on Phoenix’s Channel 12 News about ... is a minimally invasive alternative to facelifts developed by Dr. ... his team at Shapiro Aesthetic Plastic Surgery and Skin Klinic ... this exclusive news story on GenXLift. The story detailed the ...
Breaking Medicine News(10 mins):Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 2Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 4Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Dr. Daniel Shapiro Unveils New Minimally Invasive Facelift Procedure on Local Newscast 2
... 4 The Ensign Group, Inc.,(Nasdaq: ENSG ... skilled nursing,rehabilitative care services and assisted living companies, announced ... Alta, an 85-bed skilled,nursing facility in Salt Lake City, ... Center. , (Logo: ...
... Ind., Dec. 4 The holidays can become,stressful for many ... demand for time from friends, relatives and co-workers, and, this,year, ... of stress, many,people may look to give the gift of ... tree. , "Before giving ...
... Bogoch of Oncolab, Inc. have found that the concentration of replikins, ... to the mortality rate in human cancer of different cell types. ... quantitatively related to mortality rate. , ... Boston, MA ...
... In the midst of a season,of renewed focus ... States,healthcare providers from across the country are convening ... Wash., for the first U.S.,Public Sector Healthcare Provider ... technology (IT) innovations to solve real-world,problems in their ...
... are done having children feel responsible for the stored, ... than half are against implanting the embryos in anyone ... Duke University Medical Center. , "This really ... Drapkin Lyerly, MD, an obstetrician/gynecologist and bioethicist at Duke, ...
... ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading ... adult stem cells, said today that the call in ... discuss its announcement,regarding a management transition at the Company ... , The conference ...
Cached Medicine News:Health News:The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility 2Health News:A Season of Responsibility for New Pet Owners 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 2Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 4Health News:Largest study of fertility patients shows concerns about embryo disposition 2Health News:Largest study of fertility patients shows concerns about embryo disposition 3Health News:ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition 2
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
For the quantitative in vitro determination of Inorganic Phosphorous in serum....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
Medicine Products: